Dr. Martens plc (DRMTY) Fair Value & Analysis
Consumer Cyclical · US · Market cap $876M
Dr. Martens plc
DRMTY · US
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 9 days ago
Fair value updated Jun 24, 2026 — revised from $1.72 to $1.71 (−0.6%) since Jun 23, 2026. Share price −4.5% over the past month.
Price vs Fair Value (12 months)
12‑month range $1.39 – $2.43 · fair‑value band $1.10 – $2.36 · the $1.83 price screens above the $1.71 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Dr. Martens plc (DRMTY) currently trades at $1.83, while our model-based Fair Value estimate is $1.71 — implying the stock looks roughly 6.6% overvalued today. We read business quality at 65/100 (solid quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Dr. Martens plc generated revenue of $765M at a net margin of 3.1%. Revenue declined 4.3% year over year. It earns a return on equity of 6.5%. Net debt stands at $211M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Dr. Martens plc engages in the design, development, procurement, marketing, sale, and distribution of footwear. The company sells its footwear under the Dr. Martens brand name in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Dr. Martens plc reported revenue of $765M in FY2026 versus $908M in FY2022, a compound −4.2%/yr. Reported net income was $24.2M in FY2026, compounding −39.6%/yr from FY2022.
Is DRMTY fairly valued? → Check now
Similar stocks
6 more Footwear & Accessories stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| NIKE, Inc NKE | €38.07 | €45.62 | +20% |
| adidas AG 1ADS | €184.40 | €81.86 | -56% |
| ASICS Corporation ASCCY | $25.77 | $19.43 | -25% |
| Deckers Outdoor Corporation DECK | $111.18 | $125.16 | +13% |
| On Holding ONON | $38.00 | $18.63 | -51% |
| Zhejiang China Commodities City Group 600415 | ¥11.37 | ¥23.62 | +108% |
Explore undervalued stocks
More undervalued Consumer Cyclical stocks →
Frequently asked questions
Is Dr. Martens plc (DRMTY) undervalued?
What is the fair value of DRMTY?
What is the quality score of DRMTY?
What is the revenue of Dr. Martens plc (DRMTY)?
What is the net profit margin of DRMTY?
Does Dr. Martens plc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.